Sign inJoin waitlistJoin the waitlist

PL

Peter Lebowitz

CEO · University of Pennsylvania Health System

Credentials: · · ·

History

Oncology Research & Dev’t at Johnson & Johnson Division · University of Pennsylvania Health System
Present

Hematology and Medical Oncology
Internal Medicine

Research

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
New England Journal of Medicine · 2012 · 2,234 citations
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
The Lancet · 2012 · 776 citations
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
The Lancet Oncology · 2012 · 448 citations

GF
Gerald Falchook
5 papers
JI
Jeffrey Infante
4 papers
KK
Kevin Kim
4 papers
Anna Pavlick
3 papers
HB
Howard Burris
3 papers
Kevin Camphausen
3 papers
Omid Hamid
3 papers
Razelle Kurzrock
3 papers
SO
Steven O'Day
3 papers
CC
Catherine Chow
2 papers
JE
Jennifer Eng-Wong
2 papers
JZ
Jo Zujewski
2 papers